LOGIN
ID
PW
MemberShip
2024-10-22 10:17
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Is the heyday of domestic flu vaccines coming to an end?
by
Moon, sung-ho
Sep 10, 2024 05:48am
Competition among pharmaceutical and biotech companies with influenza (flu) vaccines is intensifying more than ever. As more and more companies, including global pharmaceutical companies, are seeking to supply vaccines on-site, and specialized vaccines are being launched for each age group, the competition is expected to be unprecedented thi
Company
Livtencity's introduction raises expectations in the field
by
Hwang, Byung-woo
Sep 10, 2024 05:47am
The introduction of Livtencity (maribavir), a drug that can be prescribed to manage infections in transplant patients following the use of existing treatments, has been met with positive reviews in the field due to a lack of treatment options. Although the actual number of patients who will be prescribed the drug is limited, the drug is expec
Company
Eliquis generics to enter and reshape DOAC mkt in SEP
by
Moon, Sung-ho
Sep 10, 2024 05:47am
From this month (September), numerous generic drugs will be released in the direct-acting oral anticoagulant (DOAC) market. Following Bayer's Xarelto (rivaroxaban), Pfizer and BMS's Eliquis (apixaban) is also facing its patent expiry. According to industry sources on the 26th, the Ministry of Health and Welfare recently prepared a notic
Company
Hugel hosts Train-The-Trainer seminar for global medical aes
by
Kwon Sung-Yong
Sep 9, 2024 09:45am
Hugel Inc., a leading global medical aesthetics company, said on Monday it hosted the Train-The-Trainer program at the end of August with medical experts from overseas to improve their knowledge and practices of skin rejuvenation. Some 20 medical practitioners from nine countries, including the US, Australia, Canada, China, Taiwan, Japan, Ind
Company
'Vabysmo' likely to receive approval for third indication
by
Eo, Yun-Ho
Sep 9, 2024 05:49am
'Vabysmo,' the first bispecific antibody for the treatment of ophthalmologic disease, is under review for expanded indication for retinal vein occlusion (RVO) in South Korea. According to industry sources, Roche Korea has applied for expanded approval of Vabysmo (faricimab) from the Ministry of Food and Drug Safety (MFDS). The drug receiv
Company
Jassen¡¯s Balversa can be prescribed in general hospitals
by
Eo, Yun-Ho
Sep 9, 2024 05:49am
The new bladder cancer drug Balversa may now be prescribed in general hospitals in Korea. According to industry sources, Janssen Korea¡¯s FGFR-inhibiting urothelial carcinoma (bladder cancer) drug Balversa (erdafitinib) has recently passed the drug committees (DCs) of tertiary hospitals including Seoul St. Mary's Hospital, Seoul Asan Medi
Company
Vonjo receives orphan drug designation in Korea
by
Eo, Yun-Ho
Sep 6, 2024 05:48am
The oral myelofibrosis drug Vonjo has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety announced so on the 3rd through an orphan drug designation. Specifically, the drug is indicated for ¡®adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythem
Company
SGLI2i and dulaglutide similar in reducing dementia risk
by
Hwang, Byung-woo
Sep 6, 2024 05:48am
With interest in the dementia prevention effect of Type 2 diabetes medications such as SGLT-2 inhibitors and GLP-1 RAs rising, a study has been published in Korea on the relative prevention effect between the two medications. On the 3rd, Sungkyunkwan University College of Pharmacy Professor Ju-young Shin¡¯s research team (First author: B
Company
K-made new anti-cancer drugs to unveil at conference
by
Son, Hyung-Min
Sep 6, 2024 05:48am
Korean pharmaceutical and biotech industry will unveil their positive clinical trial results at the world's largest cancer conference. The clinical outcomes of various new drug candidates from the South Korea-based pharmaceutical and biotech companies will be presented at the European Society for Medical Oncology (ESMO) Congress (ESMO 2024
Company
Padcev¡¯s reimb complex due to considerations
by
Hwang, Byung-woo
Sep 5, 2024 05:52am
Astellas Pharma Korea is continuing complex calculations for health insurance reimbursement listing of its metastatic urothelial cell carcinoma drug Padcev (enfortumab vedotin) in Korea. The reimbursement is being discussed for the second-line monotherapy indication, which was first approved. However, as the company is seeking reimbursement f
1
2
3
4
5
6
7
8
9
10
>